Document Detail


Statins and the acute coronary syndrome: 'the early bird catches the worm'.
MedLine Citation:
PMID:  16805758     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The early period following an acute coronary syndrome (ACS) is characterised by atherosclerotic plaque destabilisation and a pro-coagulant state, and is when patients are at highest risk for recurrent cardiovascular events and mortality. Statins decrease thrombus formation and increase fibrinolysis, inhibit platelet reactivity and aggregation, improve endothelial function in patients with coronary artery disease and have a major role in plaque stabilisation. Several studies showed that initiation of early statin therapy in these settings may have beneficial effects. This review summarises the current data on statins in the setting of ACSs. Known and other possible mechanisms of action are described. The pathophysiological mechanisms, histological features and biochemical characteristics of ACS are different than those with stable coronary disease, thereby suggesting that the mechanisms whereby statins exert their benefits in ACS may be distinct from those for stable CHD. Initiation of the therapy during hospitalisation rather than at the time of hospital discharge may provide protection against early recurrent cardiovascular events and also improve patients' compliance.
Authors:
P Nair; A Roguin
Related Documents :
11889008 - Relationship between lipid levels and clinical outcomes in the long-term intervention w...
10575058 - Evidence for the benefit of early intervention with pravastatin for secondary preventio...
1680788 - Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipopro...
10769278 - Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by ...
14716638 - Detecting instabilities of cardiac rhythm.
19782278 - Echocardiographic progression of a subepicardial aneurysm after inferior myocardial inf...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of clinical practice     Volume:  60     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-29     Completed Date:  2007-04-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  716-27     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Rambam Medical Center, B. Rappaport, Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
C-Reactive Protein / metabolism
Cholesterol, LDL / blood
Clinical Trials as Topic
Coronary Artery Disease / drug therapy,  physiopathology
Dose-Response Relationship, Drug
Endothelium, Vascular / physiopathology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Myocardial Ischemia / drug therapy*
Platelet Aggregation Inhibitors / therapeutic use
Risk Factors
Syndrome
Thromboxane A2 / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors; 57576-52-0/Thromboxane A2; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid ...
Next Document:  Inhaled insulin: new technology, new possibilities.